Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults

What Was Tested

This randomized controlled trial paper looks at Peptide YY and Ghrelin.

Their objective was to examine the effects of oligofructose supplementation on body weight and satiety hormone concentrations in overweight and obese adults.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Body composition (by dual-energy X-ray absorptiometry); meal tolerance tests, including satiety hormone response; food intake; and subjective appetite ratings were determined.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

As a double-blind Peptide YY study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Peptide YY could be set against what happens without it.

This study was a randomized, double-blind, placebo-controlled trial.

What Was Measured

Topics PubMed links to this paper include Area Under Curve, Blood Glucose, Dietary Supplements, Energy Intake, Ghrelin, Glucagon-Like Peptide 1 and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptide YY and Ghrelin.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (The American journal of clinical nutrition), a journal based in United States.

More context: the Peptide YY compound page and the Ghrelin compound page, all human trials.